The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature
INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012...
| Published in: | Forum of Clinical Oncology |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2015-09-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1515/fco-2015-0012 |
| Summary: | INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012 for use in metastatic soft tissue sarcoma exposed to prior chemotherapy. |
|---|---|
| ISSN: | 1792-362X |